WO2021002987A1 - High-brightness nanodot fluorophores by covalent functionalization - Google Patents

High-brightness nanodot fluorophores by covalent functionalization Download PDF

Info

Publication number
WO2021002987A1
WO2021002987A1 PCT/US2020/035568 US2020035568W WO2021002987A1 WO 2021002987 A1 WO2021002987 A1 WO 2021002987A1 US 2020035568 W US2020035568 W US 2020035568W WO 2021002987 A1 WO2021002987 A1 WO 2021002987A1
Authority
WO
WIPO (PCT)
Prior art keywords
carrier
nanodot
carriers
compound
polar
Prior art date
Application number
PCT/US2020/035568
Other languages
French (fr)
Other versions
WO2021002987A9 (en
Inventor
Yoke Khin Yap
Chee HUEI
Original Assignee
Michigan Technological University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michigan Technological University filed Critical Michigan Technological University
Priority to KR1020217043403A priority Critical patent/KR20220016920A/en
Priority to US17/615,425 priority patent/US20220226509A1/en
Priority to CN202080040136.9A priority patent/CN113892026A/en
Priority to EP20746772.1A priority patent/EP3977125A1/en
Priority to CA3139733A priority patent/CA3139733A1/en
Priority to JP2021570766A priority patent/JP2022534285A/en
Priority to CN202080074598.2A priority patent/CN114631016A/en
Priority to CA3148704A priority patent/CA3148704A1/en
Priority to EP20764562.3A priority patent/EP4018192A1/en
Priority to PCT/US2020/047378 priority patent/WO2021035135A1/en
Priority to JP2022511205A priority patent/JP2022544703A/en
Priority to KR1020227009150A priority patent/KR20220057550A/en
Priority to US17/637,018 priority patent/US20220291207A1/en
Priority to EP20792869.8A priority patent/EP4038385A1/en
Priority to JP2022519670A priority patent/JP2022549369A/en
Priority to KR1020227014362A priority patent/KR20220070512A/en
Priority to CA3152735A priority patent/CA3152735A1/en
Priority to CN202080068375.5A priority patent/CN114467026A/en
Priority to PCT/US2020/053500 priority patent/WO2021067411A1/en
Publication of WO2021002987A1 publication Critical patent/WO2021002987A1/en
Publication of WO2021002987A9 publication Critical patent/WO2021002987A9/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/533Production of labelled immunochemicals with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/6428Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0075Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/02Use of particular materials as binders, particle coatings or suspension media therefor
    • C09K11/025Use of particular materials as binders, particle coatings or suspension media therefor non-luminescent particle coatings or suspension media
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/6486Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1088Heterocyclic compounds characterised by ligands containing oxygen as the only heteroatom

Definitions

  • Fluorophores are compounds with fluorescent properties that have biomedical applications.
  • fluorophores can be used as tracers or dyes for specific staining of certain molecules or structures. More particularly, fluorophores can be used to stain tissues, cells, or materials in a variety of analytical methods, such as fluorescent imaging and spectroscopy.
  • fluorophores For the purpose of specific staining, fluorophores should be conjugated with biomolecules such as antibodies. However, reliable tracking and quantification of the fluorophores is challenging due to the low brightness and low photostability of commercial fluorophores. Therefore, a need exists for improved carrier molecules to carry fluorescent entities for biological and other applications. Other biological molecules may also benefit from improved carriers.
  • a example compound according to the present disclosure includes, among other possible things, a nanodot carrier, a moiety, and a linker having first and second functional groups, wherein the first functional group is covalently linked to the nanodot carrier, and the second functional group is covalently linked to the moiety.
  • An example method of making a nanodot carrier according to the present disclosure includes, among other possible things, mechanically processing nanodots in polar liquid to create imperfections on the nanodots, and treating the nanodots to provide polar groups at the imperfections.
  • Figure 1A schematically shows an example compound with a nanodot carrier.
  • Figures IB- 1C schematically show synthesis of an example compound like the compound of Figure 1 A from a BN nanodot carrier.
  • Figure 2A shows SEM (scanning electron microscopy) images of h-BN bulk powder.
  • Figure 2B shows SEM images of h-BN powder after mechanical processing, in this example, treatment with a homogenizer.
  • Figure 2C shows TEM (transmission electron microscopy) images of example boron nitride (BN) nanodot carriers.
  • Figure 2D shows the excitation-dependent autofluorescence of example BN nanodot carriers and the fluorescence image (inset) under UV lamp.
  • Figures 3A-B show Fourier Transform Infrared Spectroscopy (FITR) results for pristine BN nanodot carriers and processed BN nanodot carriers.
  • FITR Infrared Spectroscopy
  • Figure 4 shows the absorbance spectra of the example fluorophore, pristine carriers, and processed carriers of Figure IB.
  • Figure 5 shows fluorescence intensity of the example fluorophore, pristine carriers, and processed carriers, and processed carriers with linkers (i.e., functionalized carriers) of Figure IB.
  • high-brightness fluorophores contain a carrier element, a fluorescent element, and a linker linking the carrier element to the fluorescent element.
  • a carrier element for biomedical applications, each of the carrier element, the linker, and the fluorescent element must be biocompatible (though the requirements for biocompatibility will vary with the particular application).
  • One example carrier element is a processed nanomaterial, such as carbon nanotubes (CNT) and boron nitride nanotubes (BNNTs), both of which can be used for biomedical applications such as cellular drug delivery and spectroscopy applications.
  • CNT carbon nanotubes
  • BNNTs boron nitride nanotubes
  • fluorescent elements linked to carbon nano tubes exhibit quenching, or a reduction in the brightness of the fluorescence.
  • the compounds 20 generally comprise an inorganic nano-scale (“nanomaterial”) carrier 22, a linker 24, and a moiety 26.
  • the compound 20 includes more than one linker 24, and more than one moiety 26.
  • the carrier 22 is, in one example, a processed BNNT or CNT carrier.
  • the carrier 22 is a zero-dimensional BN“dot” (e.g., the size of the dot in all three dimensions is on the nano-scale, or less than about 100 nm), though carbon dots could also be used. In a more particular example, all three dimensions of a dot carrier are less than about 20 nm.
  • Other example carriers 22 are multi- walled BNNT or CNT carriers, where each BNNT or CNT has multiple co-axial shells of hexagonal boron nitride (h-BN for BNNTs) or graphene (for CNTs), with a typical external diameter of more than about 0.4 nm but less than about 100 nm.
  • the length of these BNNTs and CNTs is between about 1-100 nm.
  • the carrier 22 can be another nano-scale inorganic material, such as hexagonal boron nitride (h-BN) nanosheets/nanoparticles, graphene/graphite nanosheets/nanoparticles, molybdenum disulfide (M0S2) nanosheets/nanoparticles, any transition metal dichalcogenide (TMDCs) nanosheets/nanoparticles, and any nanosheets/nanoparticles of layered materials (materials with covalent layered structures that bond with van der Waals forces between layers).
  • h-BN hexagonal boron nitride
  • M0S2 molybdenum disulfide
  • TMDCs transition metal dichalcogenide
  • the linker 24 has two or more functional groups R and R’, as shown in Figures 1A-B.
  • the functional groups R and R’ are reactive groups that facilitate covalent bonding of the linker to other structures by any known chemistry.
  • R and R’ can be the same or different functional groups.
  • R and R’ can be ethoxsilane and azide, respectively.
  • R and R’ can be any known functional groups such as amine groups, carboxylic acid, isothiocyanate, maleimide, an alkyne group, a hydroxyl group, a thiol group, monosulfone, or an ester group such as a succinimidyl, sulfodichlorophenol, pentafluorophenyl or tetrafluorophenyl.
  • the linker 24 can be any type of molecule that has two or more functional groups R and R’.
  • One example linker 24 is a linear or branched polymeric molecule. In some examples, the linker 24 has a length of less than about 200 nm. In some examples, multiple linkers 24 can be connected between each other in series.
  • One functional group R interacts covalently with the carrier 22.
  • a carrier 22 with a linker 24 is known as a“functionalized” carrier 220 as shown in Figure IB. That is, when covalently linked to linker 24, the carrier 22/linker 24 structure has a functional group R’ which facilitates covalent bonding of the carrier 22/linker 24 to another moiety 26.
  • the moiety 26 is, in one example, a fluorescent entity.
  • the molecule 20 is a fluorophore.
  • the fluorescent entity is any fluorescent dye that is known in the art, including but not limited to coumarins, benzoxadiazoles, acridones, acridines, bisbenzimides, indole, benzoisoquinoline, naphthalene, anthracene, xanthene, pyrene, porphyrin, fluorescein, rhodamine, boron-dipyrromethene (BODIPY) and cyanine derivatives. Many such fluorescent dyes are commercially available.
  • the fluorescent entity can also include tandem dyes which have two different dyes connected and which interact via FRET (fluorescence resonance energy transfer). The fluorescent entity covalently interacts with the functional group R’ of linker 24 as discussed above.
  • moiety 26 is a labelling moiety or other moieties to be delivered to a human body by the carrier 22, such as antibodies, peptides, DNAs, RNAs, oligonucleotides, or the like.
  • the moiety 26, in other examples, can be molecules and chelating agents with radioactive isotopes, ferromagnetic, and/or magnetic elements.
  • the compound 20 can be used as a contrast agent for medical imaging such as PET, SPECT, CT, MRI, etc.
  • the moiety 26 can include combinations of any of the example moieties 26 discussed above.
  • the compound 20 can be used as a heterogeneous probe for biomedical detection and sensing.
  • nanomaterial carriers 22 and in particular, boron nitride (BN)-based nanomaterials, are known to be chemically inert. Therefore, it has been difficult to functionalize prior art nanomaterial carriers for covalent interactions with other structures.
  • carriers 22 such as the BN dot carrier shown in Figures 1A-C that have been subject to mechanical processing in solution or solvent, such as agitation, exhibit increased propensity to covalently interact with functional groups, such as functional group R on linker 24.
  • the solution/solvent can be the same solution/solvent in which source material is treated to form nanodots as discussed in more detail below, or a different solution/solvent.
  • nanomaterial carriers improves the solubility of the nanomaterial carriers in aqueous solutions, which can improve biocompatibility. Additionally, mechanical processing cuts carrier material into smaller pieces which can be desirable when forming dots, for example. Agitation can be accomplished by homogenizer and/or sonication, such as tip sonication or bath sonication, for instance.
  • imperfections 23 form on the carrier 22 such that localized polarities or charges are formed at the imperfections 23.
  • Polar or charged groups from the solution/solvent interact with the localized polarities or charges at the imperfections.
  • the carrier is an h-BN nanodot carrier 22.
  • imperfections 23 are disruptions in the hexagonal structure of the boron nitride material, which disruptions have localized polarity imbalances.
  • h-BN powder is treated in dimethylformamide (DMF) or another polar solution/solvent for two to four hours by using a homogenizer.
  • the treatment in polar solvent is solvothermal (e.g., the solvent/solution is heated).
  • the h-BN powder has an average particle size of between about 10-20 pm.
  • the average particle size (e.g., diameter) is about 13 pm
  • Figure 2 A shows images of example h-BN particles with average size of about 13 pm prior to treatment in DMF.
  • the homogenizer causes the BN dot carriers 22 to become smaller and remain suspended in the DMF solution.
  • the BN dot carriers 22 become smaller, and the size is reduced to less than about 2-5 pm, as shown in Figure 2B.
  • the BN dot carrier 22 suspension undergoes an agitation treatment, such as sonication.
  • an agitation treatment such as sonication.
  • the suspension is treated by bath sonication for 20-30 hours.
  • the size of the BN dot carrier 22 is reduced to about 1-3 pm after sonication.
  • the DMF/BN dot carrier 22 suspension is heat treated.
  • the suspension is heated at 150°C for 7 to 12 hours while stirring with a magnetic stir bar.
  • the stir bar ensures that the BN dot carriers 22 remain suspended in the DMF solution.
  • the carriers 22 suspension is centrifuged to precipitate large particles.
  • the suspension is centrifuged at 10,000 rpm for 10 minutes.
  • the size of the carriers 22 in the suspension is about 2-10 nm after heat treatment and centrifugation, as confirmed by TEM (transmission electron microscopy) imaging shown in Figure 2C.
  • the carriers 22 are nearly invisible using SEM imaging, confirming that the carriers 22 are very small and have dimensions in the nano-scale.
  • the carriers 22 have less than about 30 layers of h-BN, which corresponds to a thickness dimension of less than about lOOnm.
  • the length/width dimensions are also less than about 100 nm.
  • the carriers 22 have between about 4-8 layers of h-BN and have dimensions of about 2-10 nm.
  • the carriers 22 suspension undergoes solvent exchange. That is, the solvent (DMF) is switched for another solvent, water. Carriers 22 suspended in water are ready for biological applications or linking with moieties 26 to be carried, as discussed herein. Solvent exchange is accomplished as follows. DMF is evaporated into air by heating the suspension. In a particular example, the suspension is heated to 150°C until the DMF is evaporated. After heating, the remaining carriers 22 are placed into a water/ethanol mixture. In a particular example, the water/ethanol mixture is 50% water and 50% ethanol. The carriers 22/water/ethanol mixture is then heated to evaporate the ethanol at an appropriate temperature as would be known in the art. In a particular example, DMF can be removed by vacuum treatment and then the carriers 22 can be suspended in water.
  • hydrocarbon groups or fragments from the solution interact with the localized polarities at the imperfections 23 of carriers 22, though other solutions may have other polar groups that can interact with the localized polarities, such as amino, carboxylic acids, aldehyde, etc.
  • the carriers 22 can then undergo acid treatment according to any known method, which replaces the hydrocarbon groups or fragments with hydroxyl groups (-OH groups) at the imperfections 23 of carrier 22, which result in processed carriers (discussed in more detail below). Acid treatment also removes other contamination from the carriers 22, such as the hydrocarbon fragments of DMF.
  • the processed carriers can then be linked to linkers 24 by any known chemistry that causes the R group of linker 24 to link covalently with the hydroxyl groups, to form functionalized carriers 220.
  • Carriers 22 made according to the above method are autofluorescent. That is, the carriers 22 have a measurable intrinsic fluorescence.
  • Figure 2D shows fluorescence intensity of the carriers 22 shown in Figures 2A-C formed by the above method.
  • the autofluorescence may be related to imperfections 23 formed on the surfaces and edges of the carriers 22 during the above method.
  • the imperfections 23 may bond with hydrocarbon fragments of DMF, including carbon- substituted N vacancy point defects, carbene structure at zigzag edges and B02 and BO species. These imperfections 23 are expected to create a series of energy states near the edges of the valence and conduction bands of h-BN material.
  • Figures 1B-1C show synthesis of a compound 20.
  • the carrier is an h-BN carrier 22 made by treating h-BN powder in a polar organic solvent which facilitates arrangement of the h-BN into a nanodot.
  • Example polar organic solvents are dimethylformamide (DMF), N-Methyl-2-pyrrolidone (NMP), and ethanol.
  • the carriers 22 are made according to the method described above.
  • h-BN dot carriers 22 made according to the method described above are treated with acid, here, nitric acid (HNO3) to provide processed carriers 210.
  • Acid treatment causes the attachment of -OH (hydroxyl) groups to the imperfections 23, which, as discussed above, have imbalanced polarities that are attracted to the -OH groups.
  • Figures 3A-B show FTIR (Fourier Transform Infrared Spectroscopy) spectra for processed carriers 210 and non-functionalized (“pristine”) h-BN dot carriers 22. As shown in Figure 3 A, C-H stretching from DMF fragments at 2950 cm-1 of the pristine h- BN dot carriers 22 disappeared after the nitric acid treatment.
  • a broad IR (infrared) band at 3100 cm 1 is detected from the treated sample, which indicates that hydroxyl groups were introduced after acid treatment. There is a red shift on the -OH band due to the slight energy band change of zigzag edges of processed carriers 210 after DMF and contaminations were removed. The removal of these DMF fragments is also supported by the disappearance B-0 (-1255 cm-1), B-C or C-N (-1150 cm-1) bonds shown in Figure 3B. In other words, this FTIR analysis confirms the presence of hydroxyl groups on the processed carriers 210 by the presence of the expected peaks in the spectra.
  • the -OH groups attached to the imperfections 23 are themselves polar/charged.
  • the polar or charged groups e.g., -OH groups, in this example
  • the polar groups also increase the hydrophilicity of the processed carrier 210 by facilitating polar or ionic interactions with water molecules or ions in the water. Therefore, the functionalized carrier 220 exhibits improved solubility dispersion in aqueous solution as compared to other carriers that do not include the processed carriers 210.
  • the processed carriers 210 have increased capacity for attaching to linkers 24 and thus moieties 26 due to the polar or charged groups as compared to non-functionalized carriers. More specifically, the polar or charged groups act as reactive sites for covalently linking the processed carrier 210 to linker 24 via functional group R. Accordingly, the brightness of the fluorophore 20 having a functionalized carrier 220 and a fluorescent entity 26 is higher than prior art fluorophores because the functionalized carrier 220 can be linked to multiple fluorescent entities 26. More generally, the functionalized carriers 220 can be linked to more moieties 26 than non-processed carriers.
  • the BN dot carriers 22 that are processed to form processed carriers 210 as discussed above have 4 layers of h-BN that are each about 2.5 nm in diameter. Each layer can bond to 10 or more linkers 24 and fluorescent entities 26 or other moieties 26 after processing as discussed above.
  • the example processed carriers 210 can bond to 40 or more linkers 24 and fluorescent entities 26 to form a fluorophore.
  • the fluorophore 20 is thus 40 or more times brighter than a carrier with a single fluorescent entity. For branched linkers (n branches), the intensity will be as larger as 40n times that of a carrier with a single fluorescent entity.
  • the R group is a ethoxy silane group and the R’ group is an azide group.
  • the R group is reactive with processed carrier 210 at imperfections 23 (and in particular, the polar-charged groups at imperfections 23) and the R’ group is reactive with moiety 26.
  • the linker 24 is an amino-silane linkers.
  • Other linkers 24 might have a variety of functional groups such as amino, carboxylic acid, succinimdyl ester, maleimide, carboimide, pyridyldithiol, haloacetyl, aryl azide, azide, alkyne, hydrazide and monosulfone groups. Those groups could be used for the conjugation of carriers 22 to dye, drug, or any targeting material.
  • Cross-linkers which contain dual functional group can also be used to obtain functional group to conjugate linkers 24 to other entities such as dye, peptide, oligonucleotide, DNA, RNA, antibody, proteins, drugs or other nanoparticles.
  • cross linkers might be SMCC (succinimidyl 4-(N-maleimidomethyl)cyclohexane-l-carboxylate), sulfo-SMCC ((sulfo-succinimidyl 4-(N-maleimidomethyl)cyclohexane- 1-carboxylate), AMAS (N-a-maleimidoacet-oxysuccinimide ester), BMPS (N-b-maleimidopropyl- oxysuccinimide ester), GMBS (N-g-maleimidobutyryl-oxysuccinimide ester), sulfo-GMBS, MBS (m-maleimidobenzoyl-N-hydroxysuccinimide ester), sulfo-MBS, EMCS (N-e- malemidocaproyl-oxysuccinimide ester), sulfo-EMCS, SMPB (succinimidyl 4-(p- maleimidy
  • the moiety 26 is a fluorescent entity, and in particular, is FITC (fluorescein isothiocyanate), which is a green dye.
  • FITC fluorescein isothiocyanate
  • FITC can be conjugated to the linker 24 at R’ by any known chemistry.
  • a copper(I) -induced click reaction can be performed to covalently bond the R’ group of the linker 24 to an alkyne group of FITC.
  • Figure 4 shows the absorbance spectra of the example fluorophore 20 of Figure IB.
  • the characteristic absorbance signal of FITC at around 490 nm and the peak at 280 nm attributed to aromatic triazole (shown at the arrows) is present in the fluorophores 20, confirming conjugation of the processed carrier 210 with the linker 24 and FITC entity 26.
  • Figure 4 also shows the absorbance spectra of pristine carriers 22 and processed carriers 210 for comparison.
  • Figure 5 shows fluorescence intensity of the example fluorophore 20 of Figure IB after excitation with 492 nm irradiation.
  • the fluorophore 20 emits at 515 nm, the characteristic emission signal of FITC molecules. This confirms that FITC molecules are covalently conjugated on the fluorophores 20.
  • Fluorescence intensity of pristine carriers 22, processed carriers 210, and processed carriers 210 with linkers 24 i.e., functionalized carrier 220 is also shown for comparison.
  • the same chemistry e.g., copper (I)-induced click reaction discussed above
  • other known chemistries can be applied to conjugate various fluorescent entities 26 that contain alkyne functional group such as sulforhodamine alkyne, sulfo-cy5.5 alkyne, etc. to the processed carrier 210 via linkers 24.
  • alkyne functional group such as sulforhodamine alkyne, sulfo-cy5.5 alkyne, etc.
  • Other moieties 26 such as alkyne-polyethylene glycol, alkyne antibodies, etc. can also be conjugated to the processed carrier 210 via linkers 24 using the same chemistry or other known chemistries.
  • alkyl antibodies can made by reducing an antibody using DTT (Dithiothreitol), which results in reduced sulfuhydryl groups, which can then be connected to with maleimide-PEG4-alkyne or another alkyne-containing moiety according to known procedure.
  • DTT Dithiothreitol
  • Other small molecules such as sugars, nitroxides, biotin, drugs, etc. or macromolecules, peptides, DNA, RNA sequences, proteins such as SA (streptavidin and its derivatives) can also be covalently connected to the functionalized BN carrier 210/linker 24 according to known methods.
  • processed carrier 210 is made with respect to h-BN dots, carbon dots, and other nanodots of layered materials (TMDCs, etc. as discussed above) can be linked to linkers 24 by chemical means, such as by acid treatment, and then linked to moieties 26, as discussed above.
  • TMDCs nanodots of layered materials
  • BN powder was firstly exfoliated to nanosheets through a solvent exfoliation method as reported previously. Typically, 51.3 mg of BN powder and 30 mL of DMF were homogenized for 3 hours under stirring. Then it was kept under sonication at least for 24 h and then heated with stir bar for 9 hour at 150 °C. Afterwards, the resulting suspension was centrifuged for 10 min at 10000 rpm to separate the centrifuge and supernatant. The faint yellow supernatant was the BN dots (average size 2-10 nm) dispersion confirmed with TEM. DMF was removed by using high temperature the furnace under vacuum. The BN dots were stirred overnight in concentrated HNO3. Afterwards, it the mixture was neutralized by sodium hydroxide solution. It was purified through dialysis (by using MWCO 1 KDa dialysis bag). Then the sample was collected by freeze-drying.
  • the functionalized BN dots was mixed with FITC alkyne (10 nM), sodium ascorbate (7.2 mM) and copper sulfate (7.2 mM). The reaction was processing under room temperature overnight. The solvent was removed through rotation evaporation and was dispersed in 70% ethanol for dialysis purification (RE dialysis tubing 1 kDa). The sample was stored 4 °C for analysis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

Abstract

A example compound according to the present disclosure includes, among other possible things, a nanodot carrier, a moiety, and a linker having first and second functional groups, wherein the first functional group is covalently linked to the nanodot carrier, and the second functional group is covalently linked to the moiety. An example method of making a nanodot carrier is also disclosed.

Description

HIGH-BRIGHTNESS NANODOT FLUOROPHORES BY COVALENT
FUNCTIONALIZATION
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent Application Serial No. 62/855,121 filed May 31, 2019, which is hereby incorporated herein in its entirety. This application is a continuation-in-part of U.S. Patent Application Serial No. 15/953,200, filed April 13, 2018, which claims priority to U.S. Provisional Patent Application Serial No. 62/485,379, filed April 13, 2017, both of which are hereby incorporated herein in their entireties.
STATEMENT REGARDING FEDERALLY-SPONSORED RESEARCH
[0002] The inventions described herein were made with government support under Grant #1261910, Grant #1521057 and Grant # 1738466 awarded by the National Science Foundation. The Government has certain rights in this invention.
BACKGROUND
[0003] Fluorophores are compounds with fluorescent properties that have biomedical applications. For example, fluorophores can be used as tracers or dyes for specific staining of certain molecules or structures. More particularly, fluorophores can be used to stain tissues, cells, or materials in a variety of analytical methods, such as fluorescent imaging and spectroscopy.
[0004] For the purpose of specific staining, fluorophores should be conjugated with biomolecules such as antibodies. However, reliable tracking and quantification of the fluorophores is challenging due to the low brightness and low photostability of commercial fluorophores. Therefore, a need exists for improved carrier molecules to carry fluorescent entities for biological and other applications. Other biological molecules may also benefit from improved carriers. SUMMARY
[0005] A example compound according to the present disclosure includes, among other possible things, a nanodot carrier, a moiety, and a linker having first and second functional groups, wherein the first functional group is covalently linked to the nanodot carrier, and the second functional group is covalently linked to the moiety.
[0006] An example method of making a nanodot carrier according to the present disclosure includes, among other possible things, mechanically processing nanodots in polar liquid to create imperfections on the nanodots, and treating the nanodots to provide polar groups at the imperfections.
BRIEF DESCRIPTION OF THE DRAWINGS
[0007] Figure 1A schematically shows an example compound with a nanodot carrier.
[0008] Figures IB- 1C schematically show synthesis of an example compound like the compound of Figure 1 A from a BN nanodot carrier.
[0009] Figure 2A shows SEM (scanning electron microscopy) images of h-BN bulk powder.
[0010] Figure 2B shows SEM images of h-BN powder after mechanical processing, in this example, treatment with a homogenizer.
[0011] Figure 2C shows TEM (transmission electron microscopy) images of example boron nitride (BN) nanodot carriers.
[0012] Figure 2D shows the excitation-dependent autofluorescence of example BN nanodot carriers and the fluorescence image (inset) under UV lamp.
[0013] Figures 3A-B show Fourier Transform Infrared Spectroscopy (FITR) results for pristine BN nanodot carriers and processed BN nanodot carriers.
[0014] Figure 4 shows the absorbance spectra of the example fluorophore, pristine carriers, and processed carriers of Figure IB.
[0015] Figure 5 shows fluorescence intensity of the example fluorophore, pristine carriers, and processed carriers, and processed carriers with linkers (i.e., functionalized carriers) of Figure IB. DETAILED DESCRIPTION
[0016] Very generally, high-brightness fluorophores contain a carrier element, a fluorescent element, and a linker linking the carrier element to the fluorescent element. For biomedical applications, each of the carrier element, the linker, and the fluorescent element must be biocompatible (though the requirements for biocompatibility will vary with the particular application).
[0017] One example carrier element is a processed nanomaterial, such as carbon nanotubes (CNT) and boron nitride nanotubes (BNNTs), both of which can be used for biomedical applications such as cellular drug delivery and spectroscopy applications. However, it has been shown that fluorescent elements linked to carbon nano tubes exhibit quenching, or a reduction in the brightness of the fluorescence.
[0018] It has been discovered that certain fluorophores having nanomaterial carriers not only do not exhibit the quenching effect, but also exhibit brightness several orders of magnitude higher than other known fluorophores, as will be discussed herein.
[0019] Referring now to Figure 1A, fluorophore compounds 20 are shown. The compounds 20 generally comprise an inorganic nano-scale (“nanomaterial”) carrier 22, a linker 24, and a moiety 26. In some examples, the compound 20 includes more than one linker 24, and more than one moiety 26.
[0020] The carrier 22 is, in one example, a processed BNNT or CNT carrier. In the example of Figure 1A, the carrier 22 is a zero-dimensional BN“dot” (e.g., the size of the dot in all three dimensions is on the nano-scale, or less than about 100 nm), though carbon dots could also be used. In a more particular example, all three dimensions of a dot carrier are less than about 20 nm. Other example carriers 22 are multi- walled BNNT or CNT carriers, where each BNNT or CNT has multiple co-axial shells of hexagonal boron nitride (h-BN for BNNTs) or graphene (for CNTs), with a typical external diameter of more than about 0.4 nm but less than about 100 nm. The length of these BNNTs and CNTs is between about 1-100 nm. In other examples, the carrier 22 can be another nano-scale inorganic material, such as hexagonal boron nitride (h-BN) nanosheets/nanoparticles, graphene/graphite nanosheets/nanoparticles, molybdenum disulfide (M0S2) nanosheets/nanoparticles, any transition metal dichalcogenide (TMDCs) nanosheets/nanoparticles, and any nanosheets/nanoparticles of layered materials (materials with covalent layered structures that bond with van der Waals forces between layers).
[0021] The linker 24 has two or more functional groups R and R’, as shown in Figures 1A-B. The functional groups R and R’ are reactive groups that facilitate covalent bonding of the linker to other structures by any known chemistry. R and R’ can be the same or different functional groups. For example, R and R’ can be ethoxsilane and azide, respectively. R and R’ can be any known functional groups such as amine groups, carboxylic acid, isothiocyanate, maleimide, an alkyne group, a hydroxyl group, a thiol group, monosulfone, or an ester group such as a succinimidyl, sulfodichlorophenol, pentafluorophenyl or tetrafluorophenyl. The linker 24 can be any type of molecule that has two or more functional groups R and R’. One example linker 24 is a linear or branched polymeric molecule. In some examples, the linker 24 has a length of less than about 200 nm. In some examples, multiple linkers 24 can be connected between each other in series.
[0022] One functional group R interacts covalently with the carrier 22. A carrier 22 with a linker 24 is known as a“functionalized” carrier 220 as shown in Figure IB. That is, when covalently linked to linker 24, the carrier 22/linker 24 structure has a functional group R’ which facilitates covalent bonding of the carrier 22/linker 24 to another moiety 26.
[0023] The moiety 26 is, in one example, a fluorescent entity. In this example, the molecule 20 is a fluorophore. The fluorescent entity is any fluorescent dye that is known in the art, including but not limited to coumarins, benzoxadiazoles, acridones, acridines, bisbenzimides, indole, benzoisoquinoline, naphthalene, anthracene, xanthene, pyrene, porphyrin, fluorescein, rhodamine, boron-dipyrromethene (BODIPY) and cyanine derivatives. Many such fluorescent dyes are commercially available. The fluorescent entity can also include tandem dyes which have two different dyes connected and which interact via FRET (fluorescence resonance energy transfer). The fluorescent entity covalently interacts with the functional group R’ of linker 24 as discussed above.
[0024] In other examples, moiety 26 is a labelling moiety or other moieties to be delivered to a human body by the carrier 22, such as antibodies, peptides, DNAs, RNAs, oligonucleotides, or the like.
[0025] The moiety 26, in other examples, can be molecules and chelating agents with radioactive isotopes, ferromagnetic, and/or magnetic elements. In these examples, the compound 20 can be used as a contrast agent for medical imaging such as PET, SPECT, CT, MRI, etc.
[0026] In another example, the moiety 26 can include combinations of any of the example moieties 26 discussed above. In this example, the compound 20 can be used as a heterogeneous probe for biomedical detection and sensing.
[0027] Some nanomaterial carriers 22, and in particular, boron nitride (BN)-based nanomaterials, are known to be chemically inert. Therefore, it has been difficult to functionalize prior art nanomaterial carriers for covalent interactions with other structures. However, it has been discovered that carriers 22 such as the BN dot carrier shown in Figures 1A-C that have been subject to mechanical processing in solution or solvent, such as agitation, exhibit increased propensity to covalently interact with functional groups, such as functional group R on linker 24. The solution/solvent can be the same solution/solvent in which source material is treated to form nanodots as discussed in more detail below, or a different solution/solvent. Furthermore, it has been discovered that mechanical processing of nanomaterial carriers improves the solubility of the nanomaterial carriers in aqueous solutions, which can improve biocompatibility. Additionally, mechanical processing cuts carrier material into smaller pieces which can be desirable when forming dots, for example. Agitation can be accomplished by homogenizer and/or sonication, such as tip sonication or bath sonication, for instance.
[0028] Referring now to Figure IB, mechanical processing results in carrier 22 with imperfections 23. During mechanical processing in solution/solvent, imperfections 23 form on the carrier 22 such that localized polarities or charges are formed at the imperfections 23. Polar or charged groups from the solution/solvent interact with the localized polarities or charges at the imperfections. For the example, in the example of Figure IB, the carrier is an h-BN nanodot carrier 22. In this particular example, imperfections 23 are disruptions in the hexagonal structure of the boron nitride material, which disruptions have localized polarity imbalances. For example, for certain solvents/solutions, hydroxyl groups from the solvent/solution may interact with the imperfections 23, though other solvents/solutions may have other polar or charged groups that can interact with the localized imperfections 23, such as amino, carboxylic acids, or aldehyde groups, depending on the processing and type of solvent/solution. [0029] In one particular example method of making carriers 22, h-BN powder is treated in dimethylformamide (DMF) or another polar solution/solvent for two to four hours by using a homogenizer. In one example, the treatment in polar solvent is solvothermal (e.g., the solvent/solution is heated). In one example, the h-BN powder has an average particle size of between about 10-20 pm. In a particular example, the average particle size (e.g., diameter) is about 13 pm Figure 2 A shows images of example h-BN particles with average size of about 13 pm prior to treatment in DMF. The homogenizer causes the BN dot carriers 22 to become smaller and remain suspended in the DMF solution. In this example, after treatment in DMF solution, the BN dot carriers 22 become smaller, and the size is reduced to less than about 2-5 pm, as shown in Figure 2B.
[0030] After the DMF treatment, the BN dot carrier 22 suspension undergoes an agitation treatment, such as sonication. In a particular example, the suspension is treated by bath sonication for 20-30 hours. The size of the BN dot carrier 22 is reduced to about 1-3 pm after sonication.
[0031] After the agitation treatment, the DMF/BN dot carrier 22 suspension is heat treated. In a particular example, the suspension is heated at 150°C for 7 to 12 hours while stirring with a magnetic stir bar. The stir bar ensures that the BN dot carriers 22 remain suspended in the DMF solution.
[0032] Agitation and heat treatment result in carriers 22 with imperfections 23, as in the example of Figures IB.
[0033] After the heat treatment, the carriers 22 suspension is centrifuged to precipitate large particles. In a particular example, the suspension is centrifuged at 10,000 rpm for 10 minutes. In this example, the size of the carriers 22 in the suspension is about 2-10 nm after heat treatment and centrifugation, as confirmed by TEM (transmission electron microscopy) imaging shown in Figure 2C. Furthermore, the carriers 22 are nearly invisible using SEM imaging, confirming that the carriers 22 are very small and have dimensions in the nano-scale. Generally, the carriers 22 have less than about 30 layers of h-BN, which corresponds to a thickness dimension of less than about lOOnm. The length/width dimensions are also less than about 100 nm. In a particular example, the carriers 22 have between about 4-8 layers of h-BN and have dimensions of about 2-10 nm. [0034] After the centrifugation, the carriers 22 suspension undergoes solvent exchange. That is, the solvent (DMF) is switched for another solvent, water. Carriers 22 suspended in water are ready for biological applications or linking with moieties 26 to be carried, as discussed herein. Solvent exchange is accomplished as follows. DMF is evaporated into air by heating the suspension. In a particular example, the suspension is heated to 150°C until the DMF is evaporated. After heating, the remaining carriers 22 are placed into a water/ethanol mixture. In a particular example, the water/ethanol mixture is 50% water and 50% ethanol. The carriers 22/water/ethanol mixture is then heated to evaporate the ethanol at an appropriate temperature as would be known in the art. In a particular example, DMF can be removed by vacuum treatment and then the carriers 22 can be suspended in water.
[0035] It has been discovered that making carriers 22 according to the above- described method leads to a production yield orders of magnitude higher than prior art methods. For example, for the method performed with 20-30 minutes of bath sonication, heat treatment for 7 to 12 hours while stirring with a magnetic stir bar, and centrifugation at 10,000 rpm for 10 minutes, the production yield is about 47%, as compared to the reported 1- 26% for prior methods. Production yield is the weight percentage of h-BN bulk powder that become carriers 22 after the evaporation step discussed above.
[0036] For the example DMF solution, hydrocarbon groups or fragments from the solution interact with the localized polarities at the imperfections 23 of carriers 22, though other solutions may have other polar groups that can interact with the localized polarities, such as amino, carboxylic acids, aldehyde, etc. The carriers 22 can then undergo acid treatment according to any known method, which replaces the hydrocarbon groups or fragments with hydroxyl groups (-OH groups) at the imperfections 23 of carrier 22, which result in processed carriers (discussed in more detail below). Acid treatment also removes other contamination from the carriers 22, such as the hydrocarbon fragments of DMF. The processed carriers can then be linked to linkers 24 by any known chemistry that causes the R group of linker 24 to link covalently with the hydroxyl groups, to form functionalized carriers 220.
[0037] Carriers 22 made according to the above method are autofluorescent. That is, the carriers 22 have a measurable intrinsic fluorescence. Figure 2D shows fluorescence intensity of the carriers 22 shown in Figures 2A-C formed by the above method. Without being bound by any particular theory, the autofluorescence may be related to imperfections 23 formed on the surfaces and edges of the carriers 22 during the above method. The imperfections 23 may bond with hydrocarbon fragments of DMF, including carbon- substituted N vacancy point defects, carbene structure at zigzag edges and B02 and BO species. These imperfections 23 are expected to create a series of energy states near the edges of the valence and conduction bands of h-BN material.
[0038] Figures 1B-1C show synthesis of a compound 20. In this example, the carrier is an h-BN carrier 22 made by treating h-BN powder in a polar organic solvent which facilitates arrangement of the h-BN into a nanodot. Example polar organic solvents are dimethylformamide (DMF), N-Methyl-2-pyrrolidone (NMP), and ethanol. In a particular example, the carriers 22 are made according to the method described above.
[0039] In the example of Figure IB, h-BN dot carriers 22 made according to the method described above are treated with acid, here, nitric acid (HNO3) to provide processed carriers 210. Acid treatment causes the attachment of -OH (hydroxyl) groups to the imperfections 23, which, as discussed above, have imbalanced polarities that are attracted to the -OH groups. Figures 3A-B show FTIR (Fourier Transform Infrared Spectroscopy) spectra for processed carriers 210 and non-functionalized (“pristine”) h-BN dot carriers 22. As shown in Figure 3 A, C-H stretching from DMF fragments at 2950 cm-1 of the pristine h- BN dot carriers 22 disappeared after the nitric acid treatment. A broad IR (infrared) band at 3100 cm 1 is detected from the treated sample, which indicates that hydroxyl groups were introduced after acid treatment. There is a red shift on the -OH band due to the slight energy band change of zigzag edges of processed carriers 210 after DMF and contaminations were removed. The removal of these DMF fragments is also supported by the disappearance B-0 (-1255 cm-1), B-C or C-N (-1150 cm-1) bonds shown in Figure 3B. In other words, this FTIR analysis confirms the presence of hydroxyl groups on the processed carriers 210 by the presence of the expected peaks in the spectra.
[0040] The -OH groups attached to the imperfections 23 are themselves polar/charged. Turning again to Figure IB, the polar or charged groups (e.g., -OH groups, in this example) facilitate covalent interactions between the processed carrier 210 and the functional group R on linker 24. The polar groups also increase the hydrophilicity of the processed carrier 210 by facilitating polar or ionic interactions with water molecules or ions in the water. Therefore, the functionalized carrier 220 exhibits improved solubility dispersion in aqueous solution as compared to other carriers that do not include the processed carriers 210.
[0041] The processed carriers 210 have increased capacity for attaching to linkers 24 and thus moieties 26 due to the polar or charged groups as compared to non-functionalized carriers. More specifically, the polar or charged groups act as reactive sites for covalently linking the processed carrier 210 to linker 24 via functional group R. Accordingly, the brightness of the fluorophore 20 having a functionalized carrier 220 and a fluorescent entity 26 is higher than prior art fluorophores because the functionalized carrier 220 can be linked to multiple fluorescent entities 26. More generally, the functionalized carriers 220 can be linked to more moieties 26 than non-processed carriers.
[0042] In a particular example, the BN dot carriers 22 that are processed to form processed carriers 210 as discussed above have 4 layers of h-BN that are each about 2.5 nm in diameter. Each layer can bond to 10 or more linkers 24 and fluorescent entities 26 or other moieties 26 after processing as discussed above. Thus, the example processed carriers 210 can bond to 40 or more linkers 24 and fluorescent entities 26 to form a fluorophore. The fluorophore 20 is thus 40 or more times brighter than a carrier with a single fluorescent entity. For branched linkers (n branches), the intensity will be as larger as 40n times that of a carrier with a single fluorescent entity.
[0043] Turning again to Figure IB, an example triethoxysilane linker 24, which in this particular example is 3 -(Azidopropyl)triethoxy silane, is linked to the processed carrier 210. In this example, the R group is a ethoxy silane group and the R’ group is an azide group. As shown in Figure IB, the R group is reactive with processed carrier 210 at imperfections 23 (and in particular, the polar-charged groups at imperfections 23) and the R’ group is reactive with moiety 26.
[0044] In other examples, the linker 24 is an amino-silane linkers. Other linkers 24 might have a variety of functional groups such as amino, carboxylic acid, succinimdyl ester, maleimide, carboimide, pyridyldithiol, haloacetyl, aryl azide, azide, alkyne, hydrazide and monosulfone groups. Those groups could be used for the conjugation of carriers 22 to dye, drug, or any targeting material. Cross-linkers which contain dual functional group can also be used to obtain functional group to conjugate linkers 24 to other entities such as dye, peptide, oligonucleotide, DNA, RNA, antibody, proteins, drugs or other nanoparticles. Those cross linkers might be SMCC (succinimidyl 4-(N-maleimidomethyl)cyclohexane-l-carboxylate), sulfo-SMCC ((sulfo-succinimidyl 4-(N-maleimidomethyl)cyclohexane- 1-carboxylate), AMAS (N-a-maleimidoacet-oxysuccinimide ester), BMPS (N-b-maleimidopropyl- oxysuccinimide ester), GMBS (N-g-maleimidobutyryl-oxysuccinimide ester), sulfo-GMBS, MBS (m-maleimidobenzoyl-N-hydroxysuccinimide ester), sulfo-MBS, EMCS (N-e- malemidocaproyl-oxysuccinimide ester), sulfo-EMCS, SMPB (succinimidyl 4-(p- maleimidophenyl)butyrate), sulfo-SMPB, SMPH (Succinimidyl 6-((beta- maleimidopropionamido)hexanoate), LC-SMCC succinimidyl 4-(N- maleimidomethyl)cyclohexane- l-carboxy-(6-amidocaproate), sulfo-KMUS (N-K- maleimidoundecanoyl-oxysulfosuccinimide ester), SM(PEG)n where n=2,4,6,8,12,24 (PEGylated SMCC cross-linker), SPDP (succinimidyl 3-(2-pyridyldithio)propionate), LC- SPDP, sulfo-LC-SPDP, SMPT (4-succinimidyloxycarbonyl-alpha-methyl-a(2- pyridyldithio)toluene), PEGn-SPDP (where n= 2,4,12, 24), SIA (succinimidyl iodoacetate), SBAP (succinimidyl 3-(bromoacetamido)propionate), SIAP (succinimidyl (4- iodoacetyl)aminobenzoate), sulfo-SIAP, ANB-NOS (N-5-azido-2- nitrobenzoyloxysuccinimide),sulfo-SANPAH (sulfosuccinimidyl 6-(4'-azido-2'- nitrophenylamino)hexanoate), SDA (succinimidyl 4,4'-azipentanoate), sulfo-SDA, LC-SDA, sulfo-LC-SDA, SDAD (succinimidyl 2-((4,4'-azipentanamido)ethyl)-l,3'-dithiopropionate), Sulfo-SDAD, DCC (N,N'-Dicyclohexylcarbodiimide), EMCH (N-e-maleimidocaproic acid hydrazide), MPBH (4-(4-N-maleimidophenyl)butyric acid hydrazide), KMUH (N-K- maleimidoundecanoic acid hydrazide), PDPH (3-(2-pyridyldithio)propionyl hydrazide), PMPI (p-maleimidophenyl isocyanate), SPB (succinimidyl-[4-(psoralen-8-yloxy)]-butyrate), or other known linkers.
[0045] In the example of Figure IB, the moiety 26 is a fluorescent entity, and in particular, is FITC (fluorescein isothiocyanate), which is a green dye. FITC can be conjugated to the linker 24 at R’ by any known chemistry. For instance, for the azide-silane linker 24 of Figure IB, a copper(I) -induced click reaction can be performed to covalently bond the R’ group of the linker 24 to an alkyne group of FITC. [0046] Figure 4 shows the absorbance spectra of the example fluorophore 20 of Figure IB. The characteristic absorbance signal of FITC at around 490 nm and the peak at 280 nm attributed to aromatic triazole (shown at the arrows) is present in the fluorophores 20, confirming conjugation of the processed carrier 210 with the linker 24 and FITC entity 26. Figure 4 also shows the absorbance spectra of pristine carriers 22 and processed carriers 210 for comparison.
[0047] Figure 5 shows fluorescence intensity of the example fluorophore 20 of Figure IB after excitation with 492 nm irradiation. The fluorophore 20 emits at 515 nm, the characteristic emission signal of FITC molecules. This confirms that FITC molecules are covalently conjugated on the fluorophores 20. Fluorescence intensity of pristine carriers 22, processed carriers 210, and processed carriers 210 with linkers 24 (i.e., functionalized carrier 220) is also shown for comparison.
[0048] The same chemistry (e.g., copper (I)-induced click reaction discussed above) or other known chemistries can be applied to conjugate various fluorescent entities 26 that contain alkyne functional group such as sulforhodamine alkyne, sulfo-cy5.5 alkyne, etc. to the processed carrier 210 via linkers 24. Other moieties 26 such as alkyne-polyethylene glycol, alkyne antibodies, etc. can also be conjugated to the processed carrier 210 via linkers 24 using the same chemistry or other known chemistries. For example, alkyl antibodies can made by reducing an antibody using DTT (Dithiothreitol), which results in reduced sulfuhydryl groups, which can then be connected to with maleimide-PEG4-alkyne or another alkyne-containing moiety according to known procedure. Other small molecules such as sugars, nitroxides, biotin, drugs, etc. or macromolecules, peptides, DNA, RNA sequences, proteins such as SA (streptavidin and its derivatives) can also be covalently connected to the functionalized BN carrier 210/linker 24 according to known methods.
[0049] Though the preceding description of processed carrier 210 is made with respect to h-BN dots, carbon dots, and other nanodots of layered materials (TMDCs, etc. as discussed above) can be linked to linkers 24 by chemical means, such as by acid treatment, and then linked to moieties 26, as discussed above.
[0050] Example experimental method
[0051] 1. Synthesis of BN QDs [0052] BN powder was firstly exfoliated to nanosheets through a solvent exfoliation method as reported previously. Typically, 51.3 mg of BN powder and 30 mL of DMF were homogenized for 3 hours under stirring. Then it was kept under sonication at least for 24 h and then heated with stir bar for 9 hour at 150 °C. Afterwards, the resulting suspension was centrifuged for 10 min at 10000 rpm to separate the centrifuge and supernatant. The faint yellow supernatant was the BN dots (average size 2-10 nm) dispersion confirmed with TEM. DMF was removed by using high temperature the furnace under vacuum. The BN dots were stirred overnight in concentrated HNO3. Afterwards, it the mixture was neutralized by sodium hydroxide solution. It was purified through dialysis (by using MWCO 1 KDa dialysis bag). Then the sample was collected by freeze-drying.
[0053] 2. Covalent functionalization of BN dots with 3- (Azidopropyl)triethoxysilane)
[0054] Freeze-dried powder was dispersed in ethanol and toluene. Afterwards, 3- (Azidopropyl)triethoxysilane) (60 mΐ) was added in mixture. The mixture was heated to reflux and stirred under nitrogen overnight. The solvent was removed through rotation evaporation and the residue was dispersed in 70% ethanol (RE dialysis tubing 1 kDa). After dialysis, azide-silane functionalized BN dots were obtained. The sample was used directly without removing solvent.
[0055] 3. Connection BN dots with FITC
[0056] The functionalized BN dots was mixed with FITC alkyne (10 nM), sodium ascorbate (7.2 mM) and copper sulfate (7.2 mM). The reaction was processing under room temperature overnight. The solvent was removed through rotation evaporation and was dispersed in 70% ethanol for dialysis purification (RE dialysis tubing 1 kDa). The sample was stored 4 °C for analysis.
[0057] The preceding description is exemplary rather than limiting in nature. Variations and modifications to the disclosed examples may become apparent to those skilled in the art that do not necessarily depart from the essence of this invention. The scope of legal protection given to this invention can only be determined by studying the following claims.

Claims

CLAIMS What is claimed is:
1. A compound, comprising:
a nanodot carrier;
a moiety; and
a linker having first and second functional groups, wherein the first functional group is covalently linked to the nanodot carrier, and the second functional group is covalently linked to the moiety.
2. The compound of claim 1, wherein the nanodot carrier is an h-BN nanodot carrier.
3. The compound of claim 2, wherein the nanodot carrier has dimensions between about 2-10 nm.
4. The compound of claim 3, wherein the nanodot carrier comprises less than 30 layers of h-BN.
5. The compound of claim 4, wherein the nanodot carrier comprises between about 4 and 8 layers of h-BN.
6. The compound of claim 4, further comprising a plurality of linkers and a plurality of moieties, wherein each layer of the nanodot carrier is linked to 10 or more linkers of the plurality of linkers, and wherein each linker is linked to a moiety of the plurality of moieties.
7. The compound of claim 1, wherein the nanodot carrier has at least one polar group, and wherein the first functional group is covalently linked to the nanodot carrier at the at least one polar group.
8. The compound of claim 7, wherein the at least one polar group is a hydroxyl (-OH) group.
9. The compound of claim 1, wherein the moiety includes at least one of a fluorescient entity, a biological molecule, a chelating agent, and combinations thereof.
10. A method of making a nanodot carrier, comprising:
mechanically processing nanodots in polar liquid to create imperfections on the nanodots; and
treating the nanodots to provide polar groups at the imperfections.
11. The method of claim 10, further comprising covalently linking a linker to the nanodot, the linker having first and second functional groups, wherein the first functional group covalently links to the polar group.
12. The method of claim 11, further comprising covalently linking a moiety to the second functional group.
13. The method of claim 12, wherein the moiety is a fluorescent entity.
14. The method of claim 10, wherein the mechanically processing includes agitation.
15. The method of claim 14, wherein the agitation is accomplished by sonication or by homogenizer.
16. The method of claim 10, wherein the treating is an acid treatment, and wherein the polar groups are hydroxyl (-OH) groups.
17. The method of claim 10, wherein the polar liquid is dimethylformamide (DMF).
18. The method of claim 10, further comprising precipitating the nanodot carriers after the mechanical processing by centrifuging the nanodot carriers and polar liquid.
19. The method of claim 18, further comprising exchanging the polar liquid with water after the centrifuging.
20. The method of claim 19, wherein the treating is an acid treatment, and wherein the treating is performed after the exchanging.
PCT/US2020/035568 2017-04-13 2020-06-01 High-brightness nanodot fluorophores by covalent functionalization WO2021002987A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
KR1020217043403A KR20220016920A (en) 2019-05-31 2020-06-01 High Brightness Nanodot Fluorophores by Covalent Functionalization
US17/615,425 US20220226509A1 (en) 2017-04-13 2020-06-01 High-brightness nanodot fluorophores by covalent functionalization
CN202080040136.9A CN113892026A (en) 2019-05-31 2020-06-01 High brightness nanodot fluorophores through covalent functionalization
EP20746772.1A EP3977125A1 (en) 2019-05-31 2020-06-01 High-brightness nanodot fluorophores by covalent functionalization
CA3139733A CA3139733A1 (en) 2019-05-31 2020-06-01 High-brightness nanodot fluorophores by covalent functionalization
JP2021570766A JP2022534285A (en) 2019-05-31 2020-06-01 High-Brightness Nanodot Fluorescent Dyes with Covalent Functionalization
CN202080074598.2A CN114631016A (en) 2019-08-21 2020-08-21 High brightness fluorophores for quantification and phenotypic analysis of extracellular vesicles
CA3148704A CA3148704A1 (en) 2019-08-21 2020-08-21 High-brightness fluorophores for quantification and phenotyping of extracellular vesicles
EP20764562.3A EP4018192A1 (en) 2019-08-21 2020-08-21 High-brightness fluorophores for quantification and phenotyping of extracellular vesicles
PCT/US2020/047378 WO2021035135A1 (en) 2019-08-21 2020-08-21 High-brightness fluorophores for quantification and phenotyping of extracellular vesicles
JP2022511205A JP2022544703A (en) 2019-08-21 2020-08-21 Bright fluorescent dyes for extracellular vesicle quantification and phenotyping
KR1020227009150A KR20220057550A (en) 2019-08-21 2020-08-21 High-brightness fluorophores for quantification and phenotyping of extracellular vesicles
US17/637,018 US20220291207A1 (en) 2019-08-21 2020-08-21 High-brightness fluorophores for quantification and phenotyping of extracellular vesicles
EP20792869.8A EP4038385A1 (en) 2019-09-30 2020-09-30 Composite high-brightness fluorophores with controllable spectra shapes and method of using composite high-brightness fluorophores
JP2022519670A JP2022549369A (en) 2019-09-30 2020-09-30 Composite bright fluorochromes with controllable spectral shapes and methods of using composite bright fluorochromes
KR1020227014362A KR20220070512A (en) 2019-09-30 2020-09-30 Complex high-brightness fluorophores with controllable spectral morphology and methods of using complex high-brightness fluorophores
CA3152735A CA3152735A1 (en) 2019-09-30 2020-09-30 Composite high-brightness fluorophores with controllable spectra shapes and method of using composite high-brightness fluorophores
CN202080068375.5A CN114467026A (en) 2019-09-30 2020-09-30 Composite high brightness fluorophores with controllable spectral shape and methods of using the same
PCT/US2020/053500 WO2021067411A1 (en) 2019-09-30 2020-09-30 Composite high-brightness fluorophores with controllable spectra shapes and method of using composite high-brightness fluorophores

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855121P 2019-05-31 2019-05-31
US62/855,121 2019-05-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/035574 Continuation-In-Part WO2020243710A1 (en) 2017-04-13 2020-06-01 High-brightness nanotube fluorophores by covalent functionalization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/637,018 Continuation-In-Part US20220291207A1 (en) 2019-08-21 2020-08-21 High-brightness fluorophores for quantification and phenotyping of extracellular vesicles

Publications (2)

Publication Number Publication Date
WO2021002987A1 true WO2021002987A1 (en) 2021-01-07
WO2021002987A9 WO2021002987A9 (en) 2021-01-28

Family

ID=74100332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/035568 WO2021002987A1 (en) 2017-04-13 2020-06-01 High-brightness nanodot fluorophores by covalent functionalization

Country Status (6)

Country Link
EP (1) EP3977125A1 (en)
JP (1) JP2022534285A (en)
KR (1) KR20220016920A (en)
CN (1) CN113892026A (en)
CA (1) CA3139733A1 (en)
WO (1) WO2021002987A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023104026A1 (en) * 2021-12-08 2023-06-15 深圳先进技术研究院 Carbon dot nano-enzyme having near-infrared fluorescence and superoxide dismutase activity, preparation method therefor and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094884A2 (en) * 2004-03-02 2005-10-13 T-Cellic A/S Boron containing nanoparticles targeted to t-cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6340002B2 (en) * 2012-07-02 2018-06-06 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. Barrier-coated nanostructures
AU2016257431B2 (en) * 2015-05-04 2021-08-05 Cornell University Ultrasmall nanoparticles and methods of making and using same
KR102536155B1 (en) * 2017-04-13 2023-05-26 미시간 테크놀로지컬 유니버시티 High-brightness fluorophores

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094884A2 (en) * 2004-03-02 2005-10-13 T-Cellic A/S Boron containing nanoparticles targeted to t-cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLANCO-CANOSA JUAN B ET AL: "Recent progress in the bioconjugation of quantum dots", COORDINATION CHEMISTRY REVIEWS, ELSEVIER SCIENCE, AMSTERDAM, NL, vol. 263, 15 March 2014 (2014-03-15), pages 101 - 137, XP028829147, ISSN: 0010-8545, DOI: 10.1016/J.CCR.2013.08.030 *
GIOVANNI BOTTARI ET AL: "Chemical functionalization and characterization of graphene-based materials", CHEMICAL SOCIETY REVIEWS, vol. 46, no. 15, 12 July 2017 (2017-07-12), UK, pages 4464 - 4500, XP055581069, ISSN: 0306-0012, DOI: 10.1039/C7CS00229G *
KIM E. SAPSFORD ET AL: "Functionalizing Nanoparticles with Biological Molecules: Developing Chemistries that Facilitate Nanotechnology", CHEMICAL REVIEWS, vol. 113, no. 3, 22 February 2013 (2013-02-22), US, pages 1904 - 2074, XP055280274, ISSN: 0009-2665, DOI: 10.1021/cr300143v *
QUNHONG WENG ET AL: "Functionalized hexagonal boron nitride nanomaterials: emerging properties and applications", CHEMICAL SOCIETY REVIEWS, vol. 45, no. 14, 13 May 2016 (2016-05-13), UK, pages 3989 - 4012, XP055571094, ISSN: 0306-0012, DOI: 10.1039/C5CS00869G *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023104026A1 (en) * 2021-12-08 2023-06-15 深圳先进技术研究院 Carbon dot nano-enzyme having near-infrared fluorescence and superoxide dismutase activity, preparation method therefor and application thereof

Also Published As

Publication number Publication date
KR20220016920A (en) 2022-02-10
EP3977125A1 (en) 2022-04-06
JP2022534285A (en) 2022-07-28
WO2021002987A9 (en) 2021-01-28
CA3139733A1 (en) 2021-01-07
CN113892026A (en) 2022-01-04

Similar Documents

Publication Publication Date Title
Wen et al. Recent applications of carbon nanomaterials in fluorescence biosensing and bioimaging
Heister et al. Triple functionalisation of single-walled carbon nanotubes with doxorubicin, a monoclonal antibody, and a fluorescent marker for targeted cancer therapy
Bogdan et al. Carbohydrate-coated lanthanide-doped upconverting nanoparticles for lectin recognition
Huang et al. Tracking the intracellular drug release from graphene oxide using surface-enhanced Raman spectroscopy
KR102292609B1 (en) high-brightness fluorophore
Ding et al. Fluorescent detection of Mucin 1 protein based on aptamer functionalized biocompatible carbon dots and graphene oxide
US8536324B2 (en) Method of drug delivery by carbon nanotube-chitosan nanocomplexes
Assali et al. Improved non-covalent biofunctionalization of multi-walled carbon nanotubes using carbohydrate amphiphiles with a butterfly-like polyaromatic tail
Zhao et al. Preparation and characterization of the fluorescent chitosan nanoparticle probe
Nia et al. Evaluation of chemical modification effects on DNA plasmid transfection efficiency of single-walled carbon nanotube–succinate–polyethylenimine conjugates as non-viral gene carriers
Moradi et al. Application of carbon nanotubes in nanomedicine: new medical approach for tomorrow
Kim et al. Immobilization of avidin on the functionalized carbon nanotubes
EP3977125A1 (en) High-brightness nanodot fluorophores by covalent functionalization
Wang et al. Dual-color graphene quantum dots and carbon nanoparticles biosensing platform combined with Exonuclease III-assisted signal amplification for simultaneous detection of multiple DNA targets
WO2022257855A1 (en) H-bn/mos2 nanoprobe capable of achieving targeted photothermal and chemical synergistic therapy, preparation method therefor, and application thereof
McWilliams et al. Dispersion and individualization of boron nitride nanotubes
US20220226509A1 (en) High-brightness nanodot fluorophores by covalent functionalization
Prajapati et al. Surface modification strategies for the carbon nanotubes
Moon et al. Effect of nucleases on the cellular internalization of fluorescent labeled DNA-functionalized single-walled carbon nanotubes
Fei et al. The fluorescent interactions between amphiphilic chitosan derivatives and water-soluble quantum dots
KR102162923B1 (en) Nontoxic magnetofluorescent nanoparticles chelating with lanthanide complexes and the method thereof
KR20220034060A (en) High-brightness fluorophores by covalent functionalization
US20220229048A1 (en) High-brightness fluorophores by covalent functionalization
Milano et al. An alternative strategy to synthesize PNA and DNA magnetic conjugates forming nanoparticle assembly based on PNA/DNA duplexes
Hu et al. Filled and peptide-modified single-walled carbon nanotubes: synthesis, characterization, and in vitro test for cancer cell targeting

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20746772

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3139733

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021570766

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20217043403

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020746772

Country of ref document: EP

Effective date: 20220103